Cargando…

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Tofacitinib is a relatively novel therapy for immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a small-molecule drug that exerts its effects by inhibiting Janus kinases. Recently, concerns have been raised about...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bezzio, Cristina, Vernero, Marta, Ribaldone, Davide Giuseppe, Alimenti, Eleonora, Manes, Gianpiero, Saibeni, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136459/ https://www.ncbi.nlm.nih.gov/pubmed/37190126 http://dx.doi.org/10.3390/cancers15082197

Ejemplares similares

Insights into the role of gastrointestinal ultrasound in ulcerative colitis
por: Bezzio, Cristina, et al.
Publicado: (2021)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
por: Bezzio, Cristina, et al.
Publicado: (2022)

Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities
por: Manes, Gianpiero, et al.
Publicado: (2020)

Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons
por: Tontini, Gian Eugenio, et al.
Publicado: (2021)

Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology–Surgery Team to Include an Infectious Disease Specialist
por: Bezzio, Cristina, et al.
Publicado: (2021)

Tolerability of Bowel Preparation and Colonoscopy in IBD Patients: Results From a Prospective, Single-Center, Case–Control Study
por: Bezzio, Cristina, et al.
Publicado: (2020)

Efficacy of withdrawal time monitoring in adenoma detection with or without the aid of a full-spectrum scope
por: Manes, Gianpiero, et al.
Publicado: (2019)

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
por: Xu, Qingqing, et al.
Publicado: (2023)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice
por: Wang, Han, et al.
Publicado: (2019)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
por: Yang, Qiao, et al.
Publicado: (2018)

Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
por: Won, Jong Mun, et al.
Publicado: (2023)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
por: Bezzio, Cristina, et al.
Publicado: (2023)

Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis
por: Tian, Fangyuan, et al.
Publicado: (2019)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
por: Okiyama, Naoko, et al.
Publicado: (2014)

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
por: Nurmohamed, Michael, et al.
Publicado: (2018)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis
por: Huang, Chun-Hsien, et al.
Publicado: (2022)

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
por: Dragoni, Gabriele, et al.
Publicado: (2023)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Resistant Alopecia Areata Treated with Tofacitinib
por: Sahay, Govind
Publicado: (2022)

Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
por: Trontzas, Ioannis P., et al.
Publicado: (2023)

Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report
por: de Nucci, Germana, et al.
Publicado: (2020)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
por: Jiang, Zong, et al.
Publicado: (2023)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cj5si4cjkkg4h8fv77jpkpbo00